US4119774A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Heparin purification method
Assignee: Phadia AB
•
Filing: 1977-03-02
•
Granted: 1978-10-10
•
Expires: 1997-03-02
Abstract
Abstract Crude clinically used heparin preparations having a low specific activity, for example, about 130 heparin units per milligram are purified by contacting such liquid crude heparin preparations with a gel matrix complexed with (i.e. having linked to it) antithrombin or inter-alpha-trypsin inhibitor as a heparin-binding plasma protein, and then desorbing or eluting the heparin from the antithrombin or inter-alpha-trypsin inhibitor complexed gel matrix as with an applicable buffer, removing any salt in the solution with the heparin by gel filtration and then drying the heparin as by lyophilization.
Inventors
- 👤 Lars-Olov Andersson
- 👤 Erik Yngve Holmer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 13:30
CPC Classifications
C; C08; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0075
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
85 words
A method for purifying a crude heparin preparation to provide a heparin preparation of enhanced heparin specific activity, which method comprises the combination of steps of (a) contacting the starting heparin preparation with a water-insoluble gel matrix having adsorbently bound to it a heparin-binding plasma protein selected from antithrombin and inter-α-trypsin inhibitor to provide a gel matrix with adsorbently bound said plasma protein and the heparin bound thereto, and (b) separating the heparin from said gel matrix having said heparin-binding plasma protein bound to it.
Claim 2
Independent Claim
85 words
A method for purifying a crude heparin preparation to provide a heparin preparation of enhanced heparin specific activity, which method comprises the combination of steps of (a) contacting the starting heparin preparation with a water-insoluble gel matrix having adsorbently bound to it a heparin-binding plasma protein selected from antithrombin and inter-α-trypsin inhibitor to provide a gel matrix with adsorbently bound said plasma protein and the heparin bound thereto, and (b) separating the heparin from said gel matrix having said heparin-binding plasma protein bound to it.
Claim 3
Dependent Claim
19 words
The method as claimed in claim 1, wherein antithrombin is the heparin-binding plasma protein bound to the gel matrix.
Claim 4
Dependent Claim
20 words
The method as claimed in claim 1, wherein inter-alpha-trypsin inhibitor is the heparin-binding plasma protein bound to the gel matrix.
Claim 5
Dependent Claim
30 words
The method as claimed in claim 1, wherein the water-insoluble gel matrix is the beaded agarose gel prepared by having an about 4% aqueous solution of agarose in bead form.
Claim 6
Dependent Claim
21 words
The method as claimed in claim 4, wherein said agarose gel beads are activated by activation treatment with a cyanogen halide.
Claim 7
Dependent Claim
14 words
The method as claimed in claim 5, wherein the cyanogen halide is cyanogen bromide.
Claim 8
Dependent Claim
49 words
The method as claimed in claim 1, wherein the initial contact between the starting heparin preparation and the gel matrix with said adsorbently bound plasma protein is conducted by feeding said heparin preparation dissolved in a compatible aqueous buffer solution through a column packed bed of said gel matrix.
Claim 9
Dependent Claim
43 words
The method as claimed in claim 1, wherein the initial contact between the starting heparin preparation and the gel matrix with said adsorbently bound plasma protein is conducted by admixing said heparin preparation dissolved in a compatible buffer solution with said gel matrix.
Claim 10
Dependent Claim
52 words
The method as claimed in claim 1, wherein said heparin is separated from said gel matrix having the heparin bound to the gel matrix with heparin-binding plasma protein bound to it, by desorbing the heparin therefrom by elution with an aqueous solution containing about one-half percent of sodium chloride dissolved in it.
Claim 11
Dependent Claim
20 words
The method as claimed in claim 9, wherein sodium chloride in the separated heparin is removed therefrom by gel filtration.
Claim 12
Dependent Claim
15 words
The method as claimed in claim 1, wherein the separated heparin is dried by lyophilization.
References Cited (Backward Citations)
US2623001A
Cited
DE1195010B
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-10-09 | 1982-04-10 | 1982-10-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-10-09 | 1986-04-10 | 1986-10-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-10-09 | 1990-04-10 | 1990-10-10 | $7700.00 | Window Closed / Lapsed |